Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
Materials and methods to enhance hematopoietic stem cells engraftment procedures
US9107909B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9107909-B2 |
| Application number | US-200913128074-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 6, 2009 |
| Priority date | Nov 6, 2008 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE 2 biosynthesis or PGE 2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Compounds that reduce the cellular synthesis of PGE 2 include non-steroidal anti-inflammatory compounds such as indomethacin. Treatment ex vivo of HSPC with an effective amount of PGE 2 or at least one of its derivatives such as 16,16-dimethyl prostaglandin E 2 (dmPGE 2 ), promotes HSPC engraftment. Similar methods may also be used to increase viral-mediated gene transduction efficacy into HSPC.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of enhancing viral transduction efficacy in a human hematopoietic stem or progenitor cell, comprising the steps of: providing a viral vector that contains at least one gene of interest for transduction; supplying at least one human hematopoietic stem or progenitor cell that has been treated ex vivo with an effective amount of prostaglandin E 2 or a derivative thereof; and transfecting the human hematopoietic stem or progenitor cell treated with…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9107909B2 cover?
- This disclosure is directed to the methods of enhancing hematopoietic stem cells (HSPC) and progenitor cell (HSPC) engraftment procedure. Treatment in vivo of a HSPC donor with compounds that reduce PGE 2 biosynthesis or PGE 2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as AMD3100 and G-CSF, increases the circulation of available HSPCs. Comp…
- Who is the assignee on this patent?
- Pelus Louis M, Hoggatt Jonathan, Singh Pratibha, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification C12N15/86. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 18 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).